Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.30 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15466596 | 0.96 | MAPT (0.33) | SGMS1SGMS2CA12GMNNALDH1A1 | |
| SCHEMBL28367030 | 0.88 | EPAS1 (0.30) | — | |
| SCHEMBL409464 | 0.79 | HSD11B1 (0.32) | ALDH1A1LMNATDP1 | |
| SCHEMBL23629683 | 0.78 | — | — | |
| SCHEMBL961444 | 0.78 | KDM4E (0.39) | ALDH1A1LMNATDP1 | |
| SCHEMBL249375 | 0.77 | HSD11B1 (0.35) | ALDH1A1LMNATDP1 | |
| SCHEMBL250942 | 0.77 | HSD11B1 (0.35) | ALDH1A1LMNATDP1 | |
| SCHEMBL15467047 | 0.74 | — | — | |
| SCHEMBL7535152 | 0.74 | KDM4E (0.32) | ALDH1A1LMNATDP1 | |
| SCHEMBL15466664 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227433-B2 | Cycloalkylnorbornene monomers, polymers derived therefrom and their use in pervaporation | PROMERUS, LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160369026-A1 | CYCLOALKYLNORBORNENE MONOMERS, POLYMERS DERIVED THEREFROM AND THEIR USE IN PERVAPORATION | PROMERUS, LLC (US) | 2016-12-22 | — | — | US | disclosed |
| US-9468890-B2 | Cycloalkylnorbornene monomers, polymers derived therefrom and their use in pervaporation | PROMERUS, LLC (US) | 2016-10-18 | — | — | US | disclosed |
| EP-2870129-B1 | CYCLOALKYLNORBORNENE MONOMERS, POLYMERS DERIVED THEREFROM AND THEIR USE IN PERVAPORATION | SUMITOMO BAKELITE CO (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2870129-A1 | CYCLOALKYLNORBORNENE MONOMERS, POLYMERS DERIVED THEREFROM AND THEIR USE IN PERVAPORATION | Promerus, LLC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140042090-A1 | CYCLOALKYLNORBORNENE MONOMERS, POLYMERS DERIVED THEREFROM AND THEIR USE IN PERVAPORATION | PROMERUS, LLC (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014025735-A1 | CYCLOALKYLNORBORNENE MONOMERS, POLYMERS DERIVED THEREFROM AND THEIR USE IN PERVAPORATION | PROMERUS, LLC (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160369026-A1 | CYCLOALKYLNORBORNENE MONOMERS, POLYMERS DERIVED THEREFROM AND THEIR USE IN PERVAPORATION | NOTUM, AGPS, WEE1 | SGMS1 66/4885SGMS2 41/4885CA12 893/4885 |
| US-10227433-B2 | Cycloalkylnorbornene monomers, polymers derived therefrom and their use in pervaporation | NOTUM, AGPS, WEE1 | SGMS1 66/4885SGMS2 41/4885CA12 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.